InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Browse the complete record of transactions filed by HENNEMAN JOHN B III, Director. Director active across 7 companies, notably Anika Therapeutics, Inc.. In total, 13 disclosures have been published. Total volume traded: €140k. The latest transaction was filed on 8 June 2022 — Attribution. Regulator: SEC (Form 4). All data is openly available.
Declarations13 total
60,790 shares
Common Stock
SEC:0000899243-22-023836:0·
54,751 shares
Common Stock
SEC:0000899243-22-023862:0·
07,954 shares0
Common Stock
SEC:0001171843-22-004299:0·
015,943 shares0
Common Stock
SEC:0001637761-22-000096:0·
5,151 shares
Common Stock
SEC:0001628280-22-015245:0·
04,610 shares0
Common Stock
SEC:0001567619-21-012875·
04,610 shares0
Common Stock
SEC:0001567619-21-012875:0·
04,172 shares0
Common Stock
SEC:0001171843-21-004426·
04,172 shares0
Common Stock
SEC:0001171843-21-004426:0·
06,253 shares0
Common Stock
SEC:0001637761-21-000130·
06,253 shares0
Common Stock
SEC:0001637761-21-000130:0·
€70,1242,000 shares@ €35.06220.053% mcap100.0% of flow
Common Stock
SEC:0001171843-21-003679·
Ideal exit: 12 Feb 2022 (T+270)
€70,1242,000 shares@ €35.06220.035% mcap100.0% of flow
Common Stock
SEC:0001171843-21-003679:0·
Ideal exit: 12 Feb 2022 (T+270)
13 of 13 declarations
About HENNEMAN JOHN B III
John B. Henneman III is a Director at Anika Therapeutics, Inc., SeaSpine Holdings Corp, and Aprea Therapeutics, Inc. He plays a vital role in overseeing the activities and strategies of these companies. His expertise in biotechnology and medical devices allows him to make significant contributions to the boards. John is committed to promoting innovation and growth in these sectors.
